- Home
- OGEN vs KTTA Comparison
OGEN vs KTTA Comparison
Compare OGEN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- KTTA
- Stock Information
- Founded
- OGEN 1996
- KTTA 2020
- Country
- OGEN United States
- KTTA United States
- Employees
- OGEN N/A
- KTTA N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- KTTA Health Care
- Exchange
- OGEN Nasdaq
- KTTA Nasdaq
- Market Cap
- OGEN 5.4M
- KTTA 5.5M
- IPO Year
- OGEN N/A
- KTTA 2021
- Fundamental
- Price
- OGEN $1.27
- KTTA $0.73
- Analyst Decision
- OGEN
- KTTA
- Analyst Count
- OGEN 0
- KTTA 0
- Target Price
- OGEN N/A
- KTTA N/A
- AVG Volume (30 Days)
- OGEN 241.6K
- KTTA 83.7K
- Earning Date
- OGEN 11-12-2025
- KTTA 11-12-2025
- Dividend Yield
- OGEN N/A
- KTTA N/A
- EPS Growth
- OGEN N/A
- KTTA N/A
- EPS
- OGEN N/A
- KTTA N/A
- Revenue
- OGEN N/A
- KTTA N/A
- Revenue This Year
- OGEN N/A
- KTTA N/A
- Revenue Next Year
- OGEN N/A
- KTTA N/A
- P/E Ratio
- OGEN N/A
- KTTA N/A
- Revenue Growth
- OGEN N/A
- KTTA N/A
- 52 Week Low
- OGEN $1.01
- KTTA $0.65
- 52 Week High
- OGEN $18.90
- KTTA $4.57
- Technical
- Relative Strength Index (RSI)
- OGEN 46.76
- KTTA 44.70
- Support Level
- OGEN $1.27
- KTTA $0.70
- Resistance Level
- OGEN $1.45
- KTTA $0.81
- Average True Range (ATR)
- OGEN 0.08
- KTTA 0.04
- MACD
- OGEN -0.01
- KTTA -0.01
- Stochastic Oscillator
- OGEN 7.50
- KTTA 22.14
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).